• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Regulatory Information

  • Print
  • Share
  • E-mail

Fact Sheet: Breakthrough Therapies

On July 9, 2012 the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed. FDASIA Section 902 provides for a new designation - Breakthrough Therapy Designation.  A breakthrough therapy is a drug: 

  • intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition and
  • preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
If a drug is designated as breakthrough therapy, FDA will expedite the development and review of such drug.  All requests for breakthrough therapy designation will be reviewed within 60 days of receipt, and FDA will either grant or deny the request. 
 
Please refer to section 902 of FDASIA for more specific information about this provision. Additionally, a draft Guidance for Industry: Expedited Programs for Serious Conditions––Drugs and Biologics was published on June 25, 2013, and includes information such as qualifying criteria for breakthrough therapy designation, features of the breakthrough therapy program, and guidelines on how to submit a breakthrough therapy designation request.

Contact Information

Center for Drug Evaluation and Research (CDER)
If your application is reviewed in CDER the CDER Breakthrough Therapy Program Manager is:
 
Miranda Raggio, RN, BSN, MA
Phone: 301-796-0700
Email: ondeio@fda.hhs.gov
 
Center for Biologics Evaluation and Research (CBER)
If your application is reviewed in CBER, for Breakthrough Therapy Designation information contact:

Robert Yetter, Ph.D., Associate Director for Review Management
Phone: 301-827-0373
Email:   robert.yetter@fda.hhs.gov